The DOI matches its Crossref record; 104 of the 106 references it cites were found in a registry or an index.
Clinical management of adrenocortical carcinoma
Abstract
Adrenocortical carcinoma (ACC) is a rare and heterogeneous malignancy, and most of the diagnostic and therapeutic strategies are not fully established according to criteria of evidence-based medicine. However, recently collaborative efforts (e.g. International Consensus Conference 2003 and networks like the European Network for the Study of Adrenal Tumours (ENSAT)) have significantly advanced the field. This article summarizes current standards in the management of ACC. In patients with suspected ACC a thorough endocrine and imaging work-up is followed by complete (Ro) resection of the tumour by an expert surgeon and initiation of adjuvant mitotane. In advanced disease not amenable to radical resection, cytotoxic drugs will be added to mitotane. The most promising regimens (etoposide, doxorubicin, cisplatin plus mitotane and streptozotocin plus mitotane) are currently compared in an international phase-III trial. Several targeted therapies are under investigation (e.g. IGF-1 inhibitors, sunitinib, sorafenib) and may lead to new treatment options.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The median age of diagnosis is in the fifth to sixth decade, with the German ACC Registry reporting a median age at diagnosis of 46 years (9).”
From Adrenocortical carcinoma (2014) · cites this paper as [9]
In the citing paper
“Another third present with nonspecific symptoms due to local tumor growth, such as abdominal or flank pain, abdominal fullness, or early satiety (9, 10).”
From Adrenocortical carcinoma (2014) · cites this paper as [9]
In the citing paper
“For 40% to 60% of patients, the major presenting complaints are symptoms and signs of hormone excess (3, 9, 10).”
From Adrenocortical carcinoma (2014) · cites this paper as [9]
In the citing paper
“Biochemically or clinically apparent adrenocortical hormone production is evident in up to 45% to 70% (9, 10, 85).”
From Adrenocortical carcinoma (2014) · cites this paper as [9]
In the citing paper
“At the time of presentation, ACCs are generally large tumors, measuring on average 10 to 13 cm (9, 85, 89).”
From Adrenocortical carcinoma (2014) · cites this paper as [9]
In the citing paper
“Hypercortisolism is the most common presentation of patients presenting with hormone excess (50%–80% of hormone-secreting ACCs), causing classic symptoms including plethora, diabetes mellitus, muscle weakness/atrophy, and osteoporosis.”
From Adrenocortical carcinoma (2014) · cites this paper as [9]
In the citing paper
“Although earlier studies found 49% of patients with metastatic disease (stage 4) at presentation, currently only 25% to 30% of patients present with metastatic disease (9, 13, 25).”
From Adrenocortical carcinoma (2014) · cites this paper as [9]
Citations
Cites
Management of the clinically inapparent adrenal mass ("incidentaloma")
Grumbach, M. M., Biller, B. M. K., Braunstein, G. D., Campbell, K. K., Carney, J. A., Godley, P. A., Harris, E. L., Lee, J. K. T., Oertel, Y. C., Posner, M. C., et al. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-5-200303040-00013 · Cited by 945
A Survey on Adrenal Incidentaloma in Italy
Mantero, F. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.2.637 · Cited by 907
Pathologic features of prognostic significance in adrenocortical carcinoma
Weiss, L. M., Medeiros, L. J., & Vickery, A. L. (1989) · The American Journal of Surgical Pathology · doi:10.1097/00000478-198903000-00004 · Cited by 818
The clinically inapparent adrenal mass: update in diagnosis and management
Mansmann, G., Lau, J., Balk, E., Rothberg, M., Miyachi, Y., & Bornstein, S. R. (2004) · Endocrine Reviews · doi:10.1210/er.2002-0031 · Cited by 781
Adrenocortical Carcinoma: Clinical Update
Allolio, B., & Fassnacht, M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2639 · Cited by 775
Self-citationAdjuvant Mitotane Treatment for Adrenocortical Carcinoma
Terzolo, M., Angeli, A., Faßnacht, M., Daffara, F., Tauchmanovà, L., Conton, P. A., Rossetto, R., Buci, L., Sperone, P., Grossrubatscher, E. M., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa063360 · Cited by 759
Self-citationLuton, J.-P., Cerdas, S., Billaud, L., Thomas, G., Guilhaume, B., Bertagna, X., Laudat, M.-H., Louvel, A., Chapuis, Y., Blondeau, P., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199004263221705 · Cited by 717
Prevalence of adrenal incidentaloma in a contemporary computerized tomography series
Bovio, S., Cataldi, A., Reimondo, G., Sperone, P., Novello, S., Berruti, A., Borasio, P., Fava, C., Dogliotti, L., Scagliotti, G. V., et al. (2006) · Journal of Endocrinological Investigation · doi:10.1007/bf03344099 · Cited by 712
Fassnacht, M., Johanssen, S., Quinkler, M., Bucsky, P., Willenberg, H. S., Beuschlein, F., Terzolo, M., Mueller, H., Hahner, S., Allolio, B., et al. (2009) · Cancer · doi:10.1002/cncr.24030 · Cited by 695
Self-citationCharacterization of adrenal masses using unenhanced CT: an analysis of the CT literature
Boland, G. W., Lee, M. J., Gazelle, G. S., Halpern, E. F., McNicholas, M. M., & Mueller, P. R. (1998) · American Journal of Roentgenology · doi:10.2214/ajr.171.1.9648789 · Cited by 693
Research works printed but not linked: 1
- Bergenstal, 1959, Regression of adrenal cancer and suppression of adrenal function in men by o,p-DDD, Transactions of American Physicians, 72, 341
Cited by
Sorted by citations
Fassnacht, M., Arlt, W., Bancos, I., Dralle, H., Newell-Price, J., Sahdev, A., Tabarin, A., Terzolo, M., Tsagarakis, S., & Dekkers, O. M. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0467 · Cited by 1,566
Faßnacht, M., Dekkers, O. M., Else, T., Baudin, É., Berruti, A., de Krijger, R. R., Haak, H. R., Mihai, R., Assié, G., & Terzolo, M. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0608 · Cited by 976
Else, T., Kim, A. C., Sabolch, A., Raymond, V. M., Kandathil, A., Caoili, E. M., Jolly, S., Miller, B. S., Giordano, T. J., & Hammer, G. D. (2014) · Endocrine Reviews · doi:10.1210/er.2013-1029 · Cited by 892
Faßnacht, M., Tsagarakis, S., Terzolo, M., Tabarin, A., Sahdev, A., Newell-Price, J. D. C., Pelsma, I. C. M., Marina, L., Lorenz, K., Bancos, I., et al. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvad066 · Cited by 849
Adrenocortical carcinoma: a clinician’s update
Fassnacht, M., Libé, R., Kroiss, M., & Allolio, B. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.235 · Cited by 396
Self-citationKerkhofs, T. M. A., Verhoeven, R. H. A., van der Zwan, J. M., Dieleman, J. P., Kerstens, M. N., Links, T. P., van de Poll-Franse, L. V., & Haak, H. R. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.02.034 · Cited by 343
Brix, D., Allolio, B., Fenske, W., Agha, A., Dralle, H., Jurowich, C., Langer, P., Mussack, T., Nies, C., Riedmiller, H., et al. (2010) · European Urology · doi:10.1016/j.eururo.2010.06.024 · Cited by 286
Self-citationAdrenocortical carcinoma: the range of appearances on CT and MRI
Bharwani, N., Rockall, A. G., Sahdev, A., Gueorguiev, M., Drake, W., Grossman, A. B., & Reznek, R. H. (2011) · American Journal of Roentgenology · doi:10.2214/ajr.10.5540 · Cited by 215
Radiotherapy in adrenocortical carcinoma
Polat, B., Fassnacht, M., Pfreundner, L., Guckenberger, M., Bratengeier, K., Johanssen, S., Kenn, W., Hahner, S., Allolio, B., & Flentje, M. (2009) · Cancer · doi:10.1002/cncr.24331 · Cited by 189
Self-citationDevelopment of adrenal cortex zonation
Xing, Y., Lerario, A. M., Rainey, W., & Hammer, G. D. (2015) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2015.02.001 · Cited by 174
Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial
Kroiss, M., Quinkler, M., Johanssen, S., van Erp, N. P., Lankheet, N., Pöllinger, A., Laubner, K., Strasburger, C. J., Hahner, S., Müller, H.-H., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1419 · Cited by 175
Faßnacht, M., Johanssen, S., Fenske, W., Weismann, D., Agha, A., Beuschlein, F., Führer, D., Jurowich, C. F., Quinkler, M. O., Petersenn, S., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0803 · Cited by 156
Self-citationRagazzon, B., Libé, R., Gaujoux, S., Assié, G., Fratticci, A., Launay, P., Clauser, E., Bertagna, X., Tissier, F., de Reyniès, A., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2014 · Cited by 152
Hepatectomy for Noncolorectal Non-Neuroendocrine Metastatic Cancer: A Multi-Institutional Analysis
Groeschl, R. T., Nachmany, I., Steel, J. L., Reddy, S. K., Glazer, E. S., Jong, M. C. D., Pawlik, T. M., Geller, D. A., Tsung, A., Marsh, W. J., et al. (2012) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2011.12.048 · Cited by 137
Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma
Wortmann, S., Quinkler, M., Ritter, C., Kroiss, M., Johanssen, S., Hahner, S., Allolio, B., & Fassnacht, M. (2010) · European Journal of Endocrinology · doi:10.1530/eje-09-0804 · Cited by 133
Self-citationIdentification of a CpG Island Methylator Phenotype in Adrenocortical Carcinomas
Barreau, O., Assié, G., Wilmot-Roussel, H., Ragazzon, B., Baudry, C., Perlemoine, K., René-Corail, F., Bertagna, X., Dousset, B., Hamzaoui, N., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2993 · Cited by 132
The Weiss Score and Beyond—Histopathology for Adrenocortical Carcinoma
Papotti, M. G., Libé, R., Duregon, E., Volante, M., Bertherat, J. Y., & Tissier, F. (2011) · Hormones and Cancer · doi:10.1007/s12672-011-0088-0 · Cited by 132
Lombardi, C. P., Raffaelli, M., De Crea, C., Boniardi, M., De Toma, G., Marzano, L. A., Miccoli, P., Minni, F., Morino, M., Pelizzo, M. R., et al. (2012) · Surgery · doi:10.1016/j.surg.2012.08.014 · Cited by 128
Genetics and epigenetics of adrenocortical tumors
Lerário, A. M., Moraitis, A. G., & Hammer, G. D. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.10.028 · Cited by 116
New targets and therapeutic approaches for endocrine malignancies☆
Fassnacht, M., Kreissl, M. C., Weismann, D., & Allolio, B. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.03.013 · Cited by 104
Self-citationHescot, S., Slama, A., Lombès, A., Paci, A., Remy, H., Leboulleux, S., Chadarévian, R., Trabado, S., Amazit, L., Young, J., et al. (2013) · Endocrine Related Cancer · doi:10.1530/erc-12-0368 · Cited by 104
Identification of Niclosamide as a Novel Anticancer Agent for Adrenocortical Carcinoma
Satoh, K., Zhang, L., Zhang, Y., Chelluri, R. R., Boufraqech, M., Nilubol, N., Patel, D., Shen, M., & Kebebew, E. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2256 · Cited by 96
Comparison of Two Mitotane Starting Dose Regimens in Patients With Advanced Adrenocortical Carcinoma
Kerkhofs, T. M. A., Baudin, É., Terzolo, M., Allolio, B., Chadarévian, R., Mueller, H. H., Skogseid, B. M., Leboulleux, S., Mantero, F., Haak, H. R., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2281 · Cited by 94
Self-citationAdrenocortical carcinoma: effect of hospital volume on patient outcome
Lombardi, C. P., Raffaelli, M., Boniardi, M., Toma, G. D., Marzano, L. A., Miccoli, P., Minni, F., Morino, M., Pelizzo, M. R., Pietrabissa, A., et al. (2011) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-011-0866-8 · Cited by 92
Recommendation for standardized surgical management of primary adrenocortical carcinoma
Gaujoux, S., & Brennan, M. F. (2012) · Surgery · doi:10.1016/j.surg.2011.09.030 · Cited by 84
Williams, A. R., Hammer, G. D., & Else, T. (2014) · European Journal of Endocrinology · doi:10.1530/eje-13-1033 · Cited by 82
Papotti, M. G., Volante, M., Duregon, E., Delsedime, L., Terzolo, M., Berruti, A., & Rosaí, J. (2010) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181e2b726 · Cited by 81
Differences in the molecular mechanisms of adrenocortical tumorigenesis between children and adults
Faria, A. M., & Almeida, M. Q. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.09.040 · Cited by 82
Approach to the Patient with Adrenocortical Carcinoma
Lacroix, A. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0990 · Cited by 81
Kiseljak-Vassiliades, K., Bancos, I., Hamrahian, A., Habra, M. A., Vaidya, A., Levine, A. C., & Else, T. (2020) · Endocrine Practice · doi:10.4158/dscr-2020-0567 · Cited by 66
Kerkhofs, T. M. A., Verhoeven, R. H. A., Bonjer, H. J., van Dijkum, E. J. M. N., Vriens, M. R., de Vries, J., van Eijck, C. H. J., Bonsing, B. A., van de Poll-Franse, L. V., Haak, H. R., et al. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0142 · Cited by 65
Liu-Chittenden, Y., Jain, M., Gaskins, K., Wang, S., Merino, M. J., Kotian, S., Gara, S. K., Davis, S. R., Zhang, L., & Kebebew, E. (2017) · Oncogene · doi:10.1038/onc.2016.497 · Cited by 62
Fluconazole inhibits human adrenocortical steroidogenesis in vitro
van der Pas, R., Hofland, L. J., Hofland, J., TAYLOR, A. E. R., Arlt, W., Steenbergen, J., van Koetsveld, P. M., de Herder, W. W., de Jong, F. H., & Feelders, R. A. (2012) · Journal of Endocrinology · doi:10.1530/joe-12-0310 · Cited by 64
Curative Resection of Adrenocortical Carcinoma: Rates and Patterns of Postoperative Recurrence
Amini, N., Margonis, G. A., Kim, Y., Tran, T. B., Postlewait, L. M., Maithel, S. K., Wang, T. S., Evans, D. B., Hatzaras, I. S., Shenoy, R. S., et al. (2015) · Annals of Surgical Oncology · doi:10.1245/s10434-015-4810-y · Cited by 59
Future directions in the diagnosis and medical treatment of adrenocortical carcinoma
Creemers, S. G., Hofland, L. J., Korpershoek, E., Franssen, G. J. H., van Kemenade, F. J., de Herder, W. W., & Feelders, R. A. (2015) · Endocrine Related Cancer · doi:10.1530/erc-15-0452 · Cited by 61
Deficits in the Management of Patients With Adrenocortical Carcinoma in Germany
Johanssen, S., Hahner, S., Saeger, W., Quinkler, M. O., Beuschlein, F., Dralle, H., Haaf, M., Kroiß, M., Jurowich, C. F., Langer, P., et al. (2010) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2010.0885 · Cited by 60
Self-citationSirianni, R., Zolea, F., Chimento, A., Ruggiero, C., Cerquetti, L., Fallo, F., Pilon, C., Arnaldi, G., Carpinelli, G., Stigliano, A., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2374 · Cited by 58
Nakamura (2015) · doi:10.1016/j.ecl.2015.02.007 · Cited by 55
Everolimus therapy for progressive adrenocortical cancer
Fraenkel, M., Gueorguiev, M., Barak, D. F., Salmon, A. Y., Grossman, A. B., & Gross, D. J. (2013) · Endocrine · doi:10.1007/s12020-013-9878-1 · Cited by 53
Outcomes after resection of cortisol-secreting adrenocortical carcinoma
Margonis, G. A., Kim, Y., Tran, T. B., Postlewait, L. M., Maithel, S. K., Wang, T. S., Glenn, J. A., Hatzaras, I. S., Shenoy, R. S., Phay, J. E., et al. (2015) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2015.09.020 · Cited by 55
Tissier, F., Aubert, S., Leteurtre, E., Ghuzlan, A. A., Patey, M., Decaussin‐Petrucci, M., Doucet, L., Gobet, F., Hoang, C., Mazerolles, C., et al. (2012) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31825a6308 · Cited by 55
Ragazzon, B., Assié, G., & Bertherat, J. Y. (2011) · Endocrine Related Cancer · doi:10.1530/erc-10-0220 · Cited by 53
Adrenocortical carcinoma: presentation and outcome of a contemporary patient series
Kostiainen, I., Hakaste, L., Kejo, P., Parviainen, H., Laine, T., Löyttyniemi, E., Pennanen, M., Arola, J. T., Haglund, C. H., Heiskanen, I., et al. (2019) · Endocrine · doi:10.1007/s12020-019-01918-9 · Cited by 53
Fosså, A., Røsok, B. I., Kazaryan, A. М., Holte, H. J., Brennhovd, B., Westerheim, O., Marangos, I. P., & Edwin, B. (2013) · Acta Oncologica · doi:10.3109/0284186x.2013.765065 · Cited by 51
Advanced Adrenocortical Carcinoma – What to do when First-Line Therapy Fails?
Megerle, F., Kroiß, M., Hahner, S., & Faßnacht, M. (2018) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-0715-1946 · Cited by 51
Kerkhofs, T. M. A., Ettaieb, M. H. T., Verhoeven, R. H. A., Kaspers, G. J. L., Tissing, W. J. E., Loeffen, J. L. C., van den Heuvel‐Eibrink, M. M., de Krijger, R. R., & Haak, H. R. (2014) · Oncology Reports · doi:10.3892/or.2014.3506 · Cited by 52
Wu, K., Liu, Z., Liang, J., Tang, Y., Zou, Z., Zhou, C., Zhang, F., & Lu, Y. (2018) · Surgery · doi:10.1016/j.surg.2018.07.026 · Cited by 50
Pathobiology and genetics of adrenocortical carcinoma
Pittaway, J. F. H., & Guasti, L. (2018) · Journal of Molecular Endocrinology · doi:10.1530/jme-18-0122 · Cited by 49
Adrenocortical carcinoma: which surgical approach?
Carnaille, B. M. L. (2011) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-011-0852-1 · Cited by 50
Barreau, O., de Reyniès, A., Wilmot-Roussel, H., Guillaud-Bataille, M., Auzan, C., René-Corail, F., Tissier, F., Dousset, B. E., BERTAGNA, X. Y., Bertherat, J. Y., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1588 · Cited by 49
Gust, L., Taïeb, D., Beliard, A., Barlier, A., Morange, I., Micco, C. D., Henry, J., & Sebag, F. A. (2011) · World Journal of Surgery · doi:10.1007/s00268-011-1374-2 · Cited by 48
What is the best approach to an apparently nonmetastatic adrenocortical carcinoma?
Faßnacht, M., & Allolio, B. (2010) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2010.03867.x · Cited by 48
Self-citationCurrent management options for recurrent adrenocortical carcinoma
Sidhu, S. B., Glover, A. R., Ip, Zhao, J., Soon, & Robinson (2013) · OncoTargets and Therapy · doi:10.2147/ott.s34956 · Cited by 46
Rowe, N. E., Kumar, R., Schieda, N., Siddiqi, F. S., McGregor, T. B., McAlpine, K., Violette, P. D., Bathini, V., Eng, M. K., & Izard, J. (2023) · The Journal of Urology · doi:10.1097/ju.0000000000003644 · Cited by 54
Surgery in adrenocortical carcinoma: Importance of national cooperation and centralized surgery
Hermsen, I. G. C., Kerkhofs, T. M. A., den Butter, G., Kievit, J., van Eijck, C. H. J., van Dijkum, E. J. M. N., & Haak, H. R. (2012) · Surgery · doi:10.1016/j.surg.2012.02.005 · Cited by 46
Current and Emerging Therapies for Advanced Adrenocortical Carcinoma
Tacon, L. J., Prichard, R. S., Soon, P. S. H., Robinson, B. G., Clifton-Bligh, R. J., & Sidhu, S. B. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0270 · Cited by 42
Quality of life in patients with adrenal disease: A systematic review
Ho, W., & Druce, M. R. (2018) · Clinical Endocrinology · doi:10.1111/cen.13719 · Cited by 43
Stewart, P. M., & Krone, N. P. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0324-5.00015-8 · Cited by 45
Mizdrak, M., Kurir, T. T., & Božić, J. (2021) · Biomedicines · doi:10.3390/biomedicines9020174 · Cited by 44
Response to radiation therapy in adrenocortical carcinoma
Hermsen, I. G. C., Groenen, Y. E., Dercksen, M. W., Theuws, J., & Haak, H. R. (2010) · Journal of Endocrinological Investigation · doi:10.1007/bf03346675 · Cited by 42
Developing treatment for adrenocortical carcinoma
Kerkhofs, T. M. A., Ettaieb, M. H. T., Hermsen, I. G. C., & Haak, H. R. (2015) · Endocrine Related Cancer · doi:10.1530/erc-15-0318 · Cited by 41
New developments in the medical treatment of Cushing's syndrome
van der Pas, R., de Herder, W. W., Hofland, L. J., & Feelders, R. A. (2012) · Endocrine Related Cancer · doi:10.1530/erc-12-0191 · Cited by 43
Pinzani, P., Scatena, C., Salvianti, F., Corsini, E., Canu, L., Poli, G., Paglierani, M., Piccini, V., Pazzagli, M., Nesi, G., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1396 · Cited by 41
Adrenocortical Carcinoma: Current Therapeutic State-of-the-Art
Lebastchi, A. H., Kunstman, J. W., & Carling, T. (2012) · Journal of Oncology · doi:10.1155/2012/234726 · Cited by 39
Ronchi, C. L., Sbiera, S., Leich, E., Tissier, F., Steinhauer, S., Deutschbein, T., Faßnacht, M., & Allolio, B. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2669 · Cited by 41
Self-citationAdrenal MRI: Techniques and clinical applications
Siegelman, E. S. (2012) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.23601 · Cited by 40
Metastatic Adrenocortical Carcinoma: Results of 56 Pulmonary Metastasectomies in 24 Patients
den Winkel, J. O., Pfannschmidt, J., Muley, T., Grünewald, C., Dienemann, H., Faßnacht, M., & Allolio, B. (2011) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2011.07.088 · Cited by 40
Self-citationDonadille, B., Groussin, L., Waintrop, C., Abbas, H., Tenenbaum, F., Dugué, M.-A., Coste, J., BERTAGNA, X. Y., & Bertherat, J. Y. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1317 · Cited by 40
Role of the mTOR Pathway in Normal and Tumoral Adrenal Cells
Martino, M. C. D., van Koetsveld, P. M., Pivonello, R., & Hofland, L. J. (2010) · Neuroendocrinology · doi:10.1159/000314280 · Cited by 39
Delivanis, D. A., Erickson, D. Z., Atwell, T. D., Natt, N., Maraka, S., Schmit, G. D., Eiken, P. W., Nathan, M. A., Young, W. F., & Bancos, I. (2016) · Clinical Endocrinology · doi:10.1111/cen.13117 · Cited by 39
Adrenocortical tumors and insulin resistance: What is the first step?
Altieri, B., Tirabassi, G., Casa, S. D., Ronchi, C. L., Balercia, G., Orio, F., Pontecorvi, A., Colao, A., & Muscogiuri, G. (2015) · International Journal of Cancer · doi:10.1002/ijc.29950 · Cited by 39
Salomon, A., Kéramidas, M., Maisin, C., & Thomas, M. (2015) · Oncotarget · doi:10.18632/oncotarget.3222 · Cited by 38
Calissendorff, J., Calissendorff, F. S., & Falhammar, H. (2016) · BMC Endocrine Disorders · doi:10.1186/s12902-016-0095-9 · Cited by 37
Laparoscopic Adrenalectomy for Large Adrenocortical Carcinoma
Machado, N. O., Qadhi, H. A., Wahaibi, K. A., & Rizvi, S. G. A. (2015) · JSLS Journal of the Society of Laparoscopic & Robotic Surgeons · doi:10.4293/jsls.2015.00036 · Cited by 35
Genetics of Adrenocortical Development and Tumors
Lodish, M. B. (2017) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2017.01.007 · Cited by 37
Daher, M., Varghese, J. M., Gruschkus, S. K., Jiménez, C., Waguespack, S. G., Bedrose, S. S. D., Altameemi, L., Bazerbashi, H., Naing, A., Subbiah, V., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac046 · Cited by 35
The molecular basis of adrenocortical cancer
Lehmann, T. P., & Wrzesiński, T. (2012) · Cancer Genetics · doi:10.1016/j.cancergen.2012.02.009 · Cited by 34
Huynh, K. T., Lee, D. Y., Lau, B. J., Flaherty, D. C., Lee, J., & Goldfarb, M. R. (2016) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2016.05.015 · Cited by 35
Practical Considerations in the Evaluation and Management of Adrenocortical Cancer
Balasubramaniam, S., & Fojo, T. (2010) · Seminars in Oncology · doi:10.1053/j.seminoncol.2010.10.011 · Cited by 34
Langenhuijsen, J. F., Birtle, A. J., Klatte, T., Porpiglia, F., & Timsit, M. (2015) · European Urology Focus · doi:10.1016/j.euf.2015.12.001 · Cited by 34
Pediatric adrenocortical tumor – review and management update
Balderrama-Brondani, V., & Fragoso, M. C. B. V. (2020) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000540 · Cited by 35
Interventional radiology of the adrenal glands: current status
Ierardi, A. M., Petrillo, M., Patella, F., Biondetti, P., Fumarola, E. M., Angileri, S. A., Pesapane, F., Pinto, A., Dionigi, G., & Carrafiello, G. (2018) · Gland Surgery · doi:10.21037/gs.2018.01.04 · Cited by 35
Bertherat, J. Y. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3327 · Cited by 33
Targeting polo‐like kinase 1, a regulator of p53, in the treatment of adrenocortical carcinoma
Bussey, K. J., Bapat, A., Linnehan, C., Wandoloski, M., Dastrup, E., Rogers, E., Gonzales, P. A., & Demeure, M. J. (2016) · Clinical and Translational Medicine · doi:10.1186/s40169-015-0080-3 · Cited by 34
Liu‐Chittenden, Y., Jain, M., Kumar, P., Patel, D., Aufforth, R., Neychev, V. K., Sadowski, S. M., Gara, S. K., Joshi, B. H., Cottle‐Delisle, C., et al. (2015) · Cancer Medicine · doi:10.1002/cam4.449 · Cited by 33
Adrenocortical carcinoma: a literature review
Thampi, A., Shah, E., Elshimy, G., & Correa, R. (2020) · Translational Cancer Research · doi:10.21037/tcr.2019.12.28 · Cited by 32
Pathophysiology, Evaluation, and Medical Management of Adrenal Disorders
Kutikov, A., Crispen, P. L., & Uzzo, R. G. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4160-6911-9.00057-8 · Cited by 31
Landwehr, L., Schreiner, J., Appenzeller, S., Kircher, S., Herterich, S., Sbiera, S., Faßnacht, M., Kroiß, M., & Weigand, I. (2021) · European Journal of Endocrinology · doi:10.1530/eje-20-1423 · Cited by 32
Aldosterone-Secreting Adrenal Cortical Carcinoma. A Case Report and Review of the Literature
Griffin, A. C., Kelz, R. K., & LiVolsi, V. A. (2014) · Endocrine Pathology · doi:10.1007/s12022-014-9307-x · Cited by 31
How to Differentiate Benign from Malignant Adrenocortical Tumors?
Viëtor, C. L., Creemers, S. G., van Kemenade, F. J., van Ginhoven, T. M., Hofland, L. J., & Feelders, R. A. (2021) · Cancers · doi:10.3390/cancers13174383 · Cited by 33
Hatipoglu, B. (2012) · Journal of Surgical Oncology · doi:10.1002/jso.23197 · Cited by 18
Cushing’s syndrome: an update on current pharmacotherapy and future directions
Creemers, S. G., Hofland, L. J., Lamberts, S. W. J., & Feelders, R. A. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1061995 · Cited by 30
Adrenal disease: a clinical update and overview of imaging. A review
Čtvrtlík, F., Koranda, P., & Tichý, T. (2014) · Biomedical Papers · doi:10.5507/bp.2014.010 · Cited by 28
Weigand, I., Altieri, B., Lacombe, A. M. F., Basile, V., Kircher, S., Landwehr, L., Schreiner, J., Zerbini, M. C. N., Ronchi, C. L., Megerle, F., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa293 · Cited by 31
Aktuelle TNM-Klassifikationssysteme für das Nebennierenkarzinom
Faßnacht, M., Wittekind, C., & Allolio, B. (2010) · Der Pathologe · doi:10.1007/s00292-010-1306-1 · Cited by 29
Self-citationRole of Truncated O-GalNAc Glycans in Cancer Progression and Metastasis in Endocrine Cancers
Pinto, D., & Parameswaran, R. (2023) · Cancers · doi:10.3390/cancers15133266 · Cited by 28
Jong, M. C. D., Mihai, R., & Khan, S. (2020) · World Journal of Surgery · doi:10.1007/s00268-020-05868-6 · Cited by 28
Improving Outcomes in Adrenocortical Cancer: An Australian Perspective
Ip, J. C. Y., Pang, T., Glover, A. R., Soon, P. S. H., Clarke, S. J., Richardson, A. J., Campbell, P. R., Robinson, B. G., & Sidhu, S. B. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-4133-4 · Cited by 26
Effects of mitotane treatment on human steroid metabolism: implications for patient management
Ghataore, L., Chakraborti, I., Aylwin, S. J. B., Schulte, K., Dorota Dworakowska, B., Coskeran, P., & Taylor, N. (2012) · Endocrine Connections · doi:10.1530/ec-12-0028 · Cited by 26
Clinical and imaging overview of functional adrenal neoplasms
Low, G., & Sahi, K. (2012) · International Journal of Urology · doi:10.1111/j.1442-2042.2012.03014.x · Cited by 25
Metadata
- Authors
- Fassnacht, M., & Allolio, B.
- Affiliations
- University of Würzburg (DE)
- Corresponding author
- Fassnacht, Martin
- ORCID
- Fassnacht, Martin
- Venue
- Best Practice & Research Clinical Endocrinology & Metabolism
- Publisher
- Elsevier BV
- Published
- 2009-04
- Volume
- 23
- Issue
- 2
- Pages
- 273-289
- ISSN
- 1521-690X (ISSN-L)
- OpenAlex
- W2066923659
- Cited by
- 349
- References
- 106
- Citations by year
- 2026: 8 · 2025: 16 · 2024: 20 · 2023: 24 · 2022: 16 · 2021: 24 · 2020: 20 · 2019: 13 · 2018: 21 · 2017: 12 · 2016: 22 · 2015: 30 · 2014: 15 · 2013: 18 · 2012: 33
- FWCI
- 4.79
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Best Practice & Research Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Deutsche Krebshilfe
- Topics
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- adrenocortical carcinoma, adrenalectomy, cytotoxic chemotherapy, etoposide, doxorubicin, cisplatin, streptozotocin, targeted therapy, sunitinib, sorafenib, diagnostic workup, advanced disease
- MeSH terms
- Adrenal Cortex Hormones, Adrenal Cortex Neoplasms, Animals, Humans, Neoplasm Staging, Prognosis, Adrenocortical Carcinoma, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
